SCHEMBL12436973

SCHEMBL12436973

CC(=O)C1CCN(C(=O)CC2CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.53
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 1/20 0.40
TPSAB1 Q15661 1/20 0.39
TPSD1 Q9BZJ3 1/20 0.39
TPSG1 Q9NRR2 1/20 0.39
SMYD3 Q9H7B4 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
OPRM1 P35372 1/20 0.38
OPRL1 P41146 1/20 0.38
CYP1A2 P05177 1/20 0.37
CHRM4 P08173 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25512563 0.98 NAMPT (0.51) NAMPTALDH1A1NPC1TPSAB1TPSD1
SCHEMBL25498362 0.90 GNAI3 (0.46) NAMPTALDH1A1NPC1TPSAB1TPSD1
SCHEMBL12436034 0.84 ALDH1A1 (0.42) NAMPTALDH1A1NPC1L3MBTL1SMN1; SMN2
SCHEMBL6522185 0.82 L3MBTL1 (0.53) NAMPTNPC1TPSAB1TPSD1TPSG1
SCHEMBL13451572 0.80 ALDH1A1 (0.62) NAMPTALDH1A1NPC1TPSAB1TPSD1
SCHEMBL12436953 0.80 EPHX2 (0.50) ALDH1A1NPC1GAA
SCHEMBL22874790 0.78 NAMPT (0.54) NAMPTALDH1A1NPC1TPSAB1TPSD1
SCHEMBL17812266 0.78 CPN1 (0.47) ALDH1A1NPC1L3MBTL1SMN1; SMN2GAA
SCHEMBL13804082 0.78 ALDH1A1 (0.41) ALDH1A1NPC1L3MBTL1SMN1; SMN2GAA
SCHEMBL15369211 0.78 ALDH1A1 (0.41) ALDH1A1NPC1L3MBTL1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B NAMPT 2122/4885ALDH1A1 3648/4885NPC1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.